drugset
drugset / Trial / NCT07545967

Re-radiotherapy Combined With Chidamide for the Treatment of Recurrent Head and Neck Squamous Cell Carcinoma After Radiotherapy

NCT07545967 ↗

Phase 1 Recruiting 6 enrolled West China Hospital
Non-randomizedSequentialOpen-labelTreatment

Summary

To evaluate the safety and tolerability of re-irradiation combined with chidamide in patients with recurrent head and neck squamous cell carcinoma after radiotherapy.

Timeline

Start
2026-04-23
Primary completion
2027-07-01
Completion
2027-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Tucidinostat Small molecule 20 mg Oral
Subject Tucidinostat Small molecule 30 mg Oral

Indications

head and neck squamous cell carcinoma